Medical Condition News

RSS

AIR Trial demonstrates benefits of BT in asthma patients

Asthmatx Inc., today presented positive five-year data from the Asthma Intervention Research Trial, which evaluated the safety of bronchial thermoplasty with the Alair System. The data demonstrated the absence of clinical complications and the maintenance of stable lung function over a five year period post-BT in patients with moderate to severe asthma.

20 May 2010

Rising number of asthma deaths in Australia: Study

According to a study by the Australian Institute of Health and Welfare the number of people over 45 dying from asthma attacks has increased in the past five years. In 2006 402 people had died of asthma. 2005 had only 318 deaths related to asthma in comparison. 2006 saw a 40 percent hike from the preceding three years says the report.

19 May 2010

275% rise in dementia cases for Australia over next 40 years: Study

According to an Access Economics study commissioned by the Alzheimer’s Australia the number of Victorian dementia patients will quadruple in the next 40 years. At present the figures stand at 66,000 and are expected to touch 246,000 in 2050. The rise is an alarming 275% and is fueled by population growth, reduced physical activity, and an increasingly ageing population. Alzheimer’s Australia warns Victorian Health authorities to start planning for measures to curb the epidemic.

19 May 2010

Diagnostic change not enough to help children diagnosed with bipolar disorder

Shifting children from the controversial diagnosis of bipolar disorder to one that more accurately reflects their symptoms will not by itself decrease the rate of psychopharmacologic treatment and is not enough to help troubled children flourish, according to a commentary in the May 20, 2010 issue of the New England Journal of Medicine by researchers at The Hastings Center, a bioethics research institute, and a physician-researcher at Stony Brook University School of Medicine.

19 May 2010

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL.

19 May 2010

PrimeWire PRESTIGE Pressure Guide Wire receives 510(k) clearance, CE Mark approval

Volcano Corporation announced today it received both 510(k) clearance and CE Mark approval for its PrimeWire PRESTIGE Pressure Guide Wire for use with patients who have both single-vessel and multi-vessel disease. This next generation pressure wire is compatible with Volcano's full suite of integrated multi-modality consoles and stand-alone physiology systems as well as various hemodynamic monitoring systems.

19 May 2010

Rosetta Genomics announces publication of study on discovery of microRNAs in solid tumors

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study entitled, "Discovery of microRNAs and other small RNAs in solid tumors," in the online edition of Nucleic Acid Research.

19 May 2010

Riga to host 3rd Baltic Congress of Osteoporosis

Riga, Latvia will be the venue for the 3rd Baltic Congress of Osteoporosis which will take place on September 3-4, 2010. The congress, to be held in English, is jointly organized by the Latvian Osteoporosis and Bone Metabolism Diseases Association, Lithuanian Osteoporosis Foundation, Lithuanian Association of Metabolic Bone Diseases and the Estonian Osteoporosis Society.

19 May 2010

Plastic corneal prosthesis for patients unable to tolerate donor corneas

For many patients who become blind after an accident or illness, a corneal transplantation could restore the ability to see. Each year, 40,000 people in Europe - in Germany, about 7,000 - await the opportunity to be able to see again, thanks to cornea donors. But donor corneas are not common. Dr. Joachim Storsberg of the Fraunhofer Institute for Applied Polymer Research IAP in Potsdam-Golm developed material and production process for a corneal prosthesis made of plastic.

19 May 2010

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

Geron Corporation today announced positive data on its orally available small molecule telomerase activator, TAT153, in an animal model of idiopathic pulmonary fibrosis (IPF). The data show that administration of TAT153 increased telomerase activity in the lung tissue, reduced inflammation, preserved functional lung tissue, slowed disease progression and attenuated loss of pulmonary function.

19 May 2010

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent Office (USPTO) has issued a patent (US 7,704,985) entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases." The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.

19 May 2010

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.

19 May 2010

Tanning an addiction among young women

Amber Peterson, 31, used to visit tanning booths every other day for 10 years until she was diagnosed with the deadliest form of skin cancer at age 26. After surgery to remove the melanoma and several lymph nodes, this blond-haired, blue-eyed, fair-skinned woman is currently cancer-free. She has since traded in tanning beds for self-tanner in a bottle.

19 May 2010

Long-term smoking cessation success possible with treatment philosophy and individualized information

A recently completed randomized trial compared three ways to deliver a behavioral smoking cessation program using varenicline (Chantix®): by phone, web, or both. Although phone counseling had greater treatment advantage for early cessation and appeared to increase medication adherence, no differences in abstinence outcomes were seen at six months.

19 May 2010

Research team converts astroglia into two main classes of cortical neurons

The research team led by Professor Magdalena Götz of Helmholtz Zentrum München and Ludwig-Maximilians-Universität (LMU) Munich reports a major step forward in discovering a therapy for neurodegenerative diseases such as Alzheimer's or stroke. The researchers were able to convert glial cells of the brain into two different functional classes of neurons. The findings are published on May 18th in the renowned journal PLoS Biology.

19 May 2010

Study identifies suppression as a mediator between negative emotions and desire to binge

A German study published in the current issue of Psychotherapy and Psychosomatics explores what is behind binge eating.

19 May 2010

Study examines impact of APOE ε4 on cognitive function, brain anatomy in AD patients

In the most comprehensive study to date, neurologists have clearly identified significant differences in the ways that Alzheimer's disease affects patients with and without the apolipoprotein E ε4 gene, a known genetic risk factor for the neurodegenerative disease, using a combination of cognitive and neuroanatomic measures. The study found that this gene influences the way the disease manifests, even at its mildest clinical stages.

19 May 2010

Study shows 62.7% of teachers experience voice disorders on daily, weekly basis

Researchers at the University of Malaga have analysed the presence of voice disorders in male and female teachers, in order to obtain a representative statistic: 62.7% of the Early Childhood and Primary Education teaching body suffer from these complaints on a daily or weekly basis.

19 May 2010

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Cell Therapeutics, Inc. reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen. Called PIX203, the randomized trial compared CPOP-R directly to CHOP-R in the 1st line treatment of high risk patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL, NHL).

19 May 2010

Medical Condition News

AIR Trial demonstrates benefits of BT in asthma patients

Rising number of asthma deaths in Australia: Study

275% rise in dementia cases for Australia over next 40 years: Study

Diagnostic change not enough to help children diagnosed with bipolar disorder

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

PrimeWire PRESTIGE Pressure Guide Wire receives 510(k) clearance, CE Mark approval

Rosetta Genomics announces publication of study on discovery of microRNAs in solid tumors

Riga to host 3rd Baltic Congress of Osteoporosis

Plastic corneal prosthesis for patients unable to tolerate donor corneas

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Tanning an addiction among young women

Long-term smoking cessation success possible with treatment philosophy and individualized information

Research team converts astroglia into two main classes of cortical neurons

Study identifies suppression as a mediator between negative emotions and desire to binge

Study examines impact of APOE ε4 on cognitive function, brain anatomy in AD patients

Study shows 62.7% of teachers experience voice disorders on daily, weekly basis

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News